



HUNGARY

Recent changes in pharmaceutical policy measures and developments in pharmaceutical expenditure

Major changes in pharmaceutical policy in 2012-2013

Pricing

- New manufacturer payment obligation:
 - pharmaceutical products that are part of the reimbursement scheme prior to 2006 and
 - ✓ more expensive than 1000 HUF (~3 EUR)
 and
 - √ no generic products available on the market
 - → **additional 10%** payment (based on the manufacturer price as the proportion of reimbursement)
- Margin changes:
 - √ wholesale margin ↓
 - √ pharmacy margin ↑

but no changes in overall margin

Reimbursement

- Technical modifications in the reference price system:
 - ✓ preferential reference price tier change
 - ✓ changes in criteria for reference products
- "Registry" based reimbursement: reimbursement based on individual patient treatment information sheet (~registry)
 - ✓ TNF-alfa inhibitors
 - ✓ certain oncology products
 - √ enzyme preparations
- Biotech products (epo and cytokine) prescription quotas::
 - ✓ first year: 40% cheapest products
 - second year: 70% cheapest products

Other changes

 Pharmacist can check the patients drug purchase history (if the patient agrees) from April 2013


Outlook

No changes

Development of pharmaceutical expenditure in the last 5 available years

Out-patient sector

Hungary – out-patient pharmaceutical expenditure per capita in EURO



Data source:

KSH (Hungarian Central Statistical Office): data provider for OECD Health Database

Data definition:

Prescribed medicines and Over-the counter medicines

In-patient sector

No data available

Impact of measures and evaluation

No data available